Esperion Theraps Inc Drug Patent Portfolio
Esperion Theraps Inc owns 2 orange book drugs protected by 11 US patents Given below is the list of Esperion Theraps Inc's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11613511 | Methods of making bempedoic acid and compositions of the same | 19 Jun, 2040 | Active |
| US11760714 | Methods of making bempedoic acid and compositions of the same | 19 Jun, 2040 | Active |
| US11926584 | Methods of making bempedoic acid and compositions of the same | 19 Jun, 2040 | Active |
| US11744816 | Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease | 14 Mar, 2036 | Active |
| US10912751 | Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease | 14 Mar, 2036 | Active |
| US7335799 | Hydroxyl compounds and compositions for cholesterol management and related uses | 03 Dec, 2030 | Active |
| US10118881 | Hydroxyl compounds and compositions for cholesterol management and related uses | 23 Dec, 2023 | Expired |
| US10941095 | Hydroxyl compounds and compositions for cholesterol management and related uses | 23 Dec, 2023 | Expired |
| US8497301 | Hydroxyl compounds and compositions for cholesterol management and related uses | 23 Dec, 2023 | Expired |
| US9000041 | Hydroxyl compounds and compositions for cholesterol management and related uses | 23 Dec, 2023 | Expired |
| US9624152 | Hydroxyl compounds and compositions for cholesterol management and related uses | 23 Dec, 2023 | Expired |
Latest Legal Activities on Esperion Theraps Inc's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Esperion Theraps Inc.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 12 Jul, 2024 | US10912751 |
| Mail O.P. Petition Decision | 17 Jun, 2024 | US7335799 |
|
Email Notification
Critical
| 17 Jun, 2024 | US7335799 |
| Mail O.P. Petition Decision | 17 Jun, 2024 | US7335799 |
|
Email Notification
Critical
| 17 Jun, 2024 | US7335799 |
| Mail-Record Petition Decision of Granted to Make Entity Status large | 13 Jun, 2024 | US7335799 |
| Mail-Record Petition Decision of Granted to Make Entity Status large | 13 Jun, 2024 | US7335799 |
| O.P. Petition Decision | 12 Jun, 2024 | US7335799 |
| Record Petition Decision of Granted to Make Entity Status large | 12 Jun, 2024 | US7335799 |
| O.P. Petition Decision | 12 Jun, 2024 | US7335799 |
| Record Petition Decision of Granted to Make Entity Status large | 12 Jun, 2024 | US7335799 |
|
Patent Term Extension Certificate
Critical
| 13 May, 2024 | US7335799 |
|
Patent Term Extension Certificate
Critical
| 13 May, 2024 | US7335799 |
| Notice of Final Determination -Eligible | 04 Apr, 2024 | US7335799 |
| Notice of Final Determination -Eligible | 04 Apr, 2024 | US7335799 |
Esperion Theraps Inc's Family Patents
Esperion Theraps Inc drugs have patent protection in a total of 24 countries. It's US patent count contributes only to 40.6% of its total global patent coverage. Click
below to unlock the full patent family tree.
Esperion Theraps Inc Drug List
Given below is the complete list of Esperion Theraps Inc's drugs and the patents protecting them.
1. Nexletol
Nexletol is protected by 10 patents, out of which 5 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11613511 | Methods of making bempedoic acid and compositions of the same |
19 Jun, 2040
(15 years from now)
| Active |
| US11760714 | Methods of making bempedoic acid and compositions of the same |
19 Jun, 2040
(15 years from now)
| Active |
| US11926584 | Methods of making bempedoic acid and compositions of the same |
19 Jun, 2040
(15 years from now)
| Active |
| US11744816 | Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease |
14 Mar, 2036
(10 years from now)
| Active |
| US7335799 | Hydroxyl compounds and compositions for cholesterol management and related uses |
03 Dec, 2030
(5 years from now)
| Active |
| US10118881 | Hydroxyl compounds and compositions for cholesterol management and related uses |
23 Dec, 2023
(1 year, 4 months ago)
| Expired |
| US10941095 | Hydroxyl compounds and compositions for cholesterol management and related uses |
23 Dec, 2023
(1 year, 4 months ago)
| Expired |
| US8497301 | Hydroxyl compounds and compositions for cholesterol management and related uses |
23 Dec, 2023
(1 year, 4 months ago)
| Expired |
| US9000041 | Hydroxyl compounds and compositions for cholesterol management and related uses |
23 Dec, 2023
(1 year, 4 months ago)
| Expired |
| US9624152 | Hydroxyl compounds and compositions for cholesterol management and related uses |
23 Dec, 2023
(1 year, 4 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Nexletol's drug page
2. Nexlizet
Nexlizet is protected by 11 patents, out of which 5 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11613511 | Methods of making bempedoic acid and compositions of the same |
19 Jun, 2040
(15 years from now)
| Active |
| US11760714 | Methods of making bempedoic acid and compositions of the same |
19 Jun, 2040
(15 years from now)
| Active |
| US11926584 | Methods of making bempedoic acid and compositions of the same |
19 Jun, 2040
(15 years from now)
| Active |
| US10912751 | Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease |
14 Mar, 2036
(10 years from now)
| Active |
| US11744816 | Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease |
14 Mar, 2036
(10 years from now)
| Active |
| US7335799 | Hydroxyl compounds and compositions for cholesterol management and related uses |
03 Dec, 2030
(5 years from now)
| Active |
| US10118881 | Hydroxyl compounds and compositions for cholesterol management and related uses |
23 Dec, 2023
(1 year, 4 months ago)
| Expired |
| US10941095 | Hydroxyl compounds and compositions for cholesterol management and related uses |
23 Dec, 2023
(1 year, 4 months ago)
| Expired |
| US8497301 | Hydroxyl compounds and compositions for cholesterol management and related uses |
23 Dec, 2023
(1 year, 4 months ago)
| Expired |
| US9000041 | Hydroxyl compounds and compositions for cholesterol management and related uses |
23 Dec, 2023
(1 year, 4 months ago)
| Expired |
| US9624152 | Hydroxyl compounds and compositions for cholesterol management and related uses |
23 Dec, 2023
(1 year, 4 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Nexlizet's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List